These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
485 related articles for article (PubMed ID: 28916749)
1. Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8 Fehlings M; Simoni Y; Penny HL; Becht E; Loh CY; Gubin MM; Ward JP; Wong SC; Schreiber RD; Newell EW Nat Commun; 2017 Sep; 8(1):562. PubMed ID: 28916749 [TBL] [Abstract][Full Text] [Related]
2. Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies. Li S; Simoni Y; Zhuang S; Gabel A; Ma S; Chee J; Islas L; Cessna A; Creaney J; Bradley RK; Redwood A; Robinson BW; Newell EW Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34285073 [TBL] [Abstract][Full Text] [Related]
3. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity. Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075 [TBL] [Abstract][Full Text] [Related]
4. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1 Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236 [TBL] [Abstract][Full Text] [Related]
14. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Allard B; Pommey S; Smyth MJ; Stagg J Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257 [TBL] [Abstract][Full Text] [Related]
15. 4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation. Qu QX; Zhu XY; Du WW; Wang HB; Shen Y; Zhu YB; Chen C Front Immunol; 2020; 11():577. PubMed ID: 32391001 [TBL] [Abstract][Full Text] [Related]
16. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837 [TBL] [Abstract][Full Text] [Related]
17. Combinatorial immunotherapy induces tumor-infiltrating CD8 Van Braeckel-Budimir N; Dolina JS; Wei J; Wang X; Chen SH; Santiago P; Tu G; Micci L; Al-Khami AA; Pfister S; Ram S; Sundar P; Thomas G; Long H; Yang W; Potluri S; Salek-Ardakani S J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903555 [TBL] [Abstract][Full Text] [Related]
18. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098 [TBL] [Abstract][Full Text] [Related]
19. Bystander CD8 Simoni Y; Becht E; Fehlings M; Loh CY; Koo SL; Teng KWW; Yeong JPS; Nahar R; Zhang T; Kared H; Duan K; Ang N; Poidinger M; Lee YY; Larbi A; Khng AJ; Tan E; Fu C; Mathew R; Teo M; Lim WT; Toh CK; Ong BH; Koh T; Hillmer AM; Takano A; Lim TKH; Tan EH; Zhai W; Tan DSW; Tan IB; Newell EW Nature; 2018 May; 557(7706):575-579. PubMed ID: 29769722 [TBL] [Abstract][Full Text] [Related]
20. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression. Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]